Reproducibility of Continuous Glucose Monitoring (CGM) in the Assessment of Glucose Metabolism Disorders in Children With Cystic Fibrosis

Glucose metabolism disorders in cystic fibrosis (CF-GMD) are common and have a negative clinical impact. Screening currently relies on the oral glucose tolerance test (OGTT); however, this procedure is burdensome and complex for both patients and healthcare providers. Continuous glucose monitoring (CGM) is increasingly used in CF centers for CF-GMD screening, either alone or alongside the OGTT. While long-term (one-year) OGTT reproducibility is known to be poor, the short- and medium-term reproducibility of CGM remains unknown. This examination is poised to become a major tool in CF-GMD investigation, upon which critical therapeutic decisions could be based. The primary objective of this project is to evaluate the short-term variability of CGM data.

Inclusion Criteria: * Patients aged 10 to 17 years * Diagnosed with cystic fibrosis (CF) * Managed by the pediatric CF care center (CRCM) of the Groupement Hospitalier Est * Patients presenting with one of the following three stages are included: normal glucose tolerance with or without indeterminate glucose tolerance (INDET), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) Exclusion Criteria: * Patients with treated or untreated diabetes * Patients presenting with a pulmonary exacerbation and currently receiving antibiotic therapy * Patients participating in another clinical trial that could interfere, in the investigator's judgment, with the study findings * Refusal of the patient and/or the legal guardian(s) to participate in the study * Pregnant, parturient, or breastfeeding women * Persons deprived of liberty by a judicial or administrative decision * Persons undergoing psychiatric care * Persons admitted to a healthcare or social institution for purposes other than research * Persons not affiliated with a social security scheme or beneficiaries of a similar scheme